Robert C Flanigan
Overview
Explore the profile of Robert C Flanigan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
1593
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Ellis J, Sontag-Milobsky I, Chen V, Rac G, Hartman N, Gorbonos A, et al.
Urol Oncol
. 2024 Oct;
42(12):454.e1-454.e7.
PMID: 39370308
Introduction: Renal parenchymal volume loss from standard partial nephrectomy (SPN) is a significant prognosticator for postoperative renal function. Tumor enucleation (TE) minimizes parenchymal loss compared to SPN. Little is known...
3.
Chen V, James C, Khemmani M, Desai S, Doshi C, Rac G, et al.
Prostate
. 2024 Jul;
84(13):1251-1261.
PMID: 38946139
Background: The link between the prostate microbiome and prostate cancer remains unclear. Few studies have analyzed the microbiota of prostate tissue, and these have been limited by potential contamination by...
4.
MRI at diagnostic versus confirmatory biopsy during MRI-based active surveillance of prostate cancer
Marras M, Ellis J, Copelan O, Naha U, Han T, Rac G, et al.
Urol Oncol
. 2024 Jun;
42(10):331.e1-331.e6.
PMID: 38890040
Objectives: Active surveillance (AS) is a management strategy for patients with favorable risk prostate cancer. Multi-parametric magnetic resonance imaging (mpMRI) may impact upgrading rates, but there is mixed evidence on...
5.
Patel H, Halgrimson W, Sweigert S, Shea S, Turk T, Quek M, et al.
BJUI Compass
. 2024 Feb;
5(2):304-312.
PMID: 38371209
Objectives: The aim of this study is to evaluate the impact of radiologist and urologist variability on detection of prostate cancer (PCa) and clinically significant prostate cancer (csPCa) with magnetic...
6.
Hekman L, Napierkowski E, Hartman N, Ellis J, Wagner R, Bova D, et al.
Case Rep Surg
. 2023 Dec;
2023:1458175.
PMID: 38125746
Prostate-specific membrane antigen positron emission tomography (PSMA PET) has been approved by the Food and Drug Administration (FDA) to identify prostate cancer in the setting of biochemical recurrence but can...
7.
Blackwell R, Kandabarow A, Gupta G, Harkenrider M, Quek M, Flanigan R
Urol Pract
. 2023 Aug;
2(6):349-358.
PMID: 37559322
Introduction: Approximately 25% of patients diagnosed with prostate cancer choose radiation therapy as the primary treatment for this malignancy. Urinary tract toxicity after radiation therapy impacts patients years after treatment...
8.
Van Kuiken M, Blackwell R, Bisanz B, Joyce C, Yacoub J, Shea S, et al.
Urol Pract
. 2023 Jun;
6(2):117-122.
PMID: 37312382
Introduction: Using a combination of magnetic resonance imaging of the prostate and prostate specific antigen density, we determined which men on active surveillance are at risk for up staging and...
9.
Pahouja G, Patel H, Desai S, Rac G, Cheng T, Okabe Y, et al.
Urol Oncol
. 2022 Nov;
41(1):48.e11-48.e18.
PMID: 36441068
Introduction: Ductal adenocarcinoma (DA) and intraductal carcinoma (IDC) of the prostate are associated with higher stage disease at radical prostatectomy (RP). We evaluated diagnostic accuracy of biopsy, MRI-visibility, and outcomes...
10.
Patel H, Okabe Y, Rac G, Pahouja G, Desai S, Shea S, et al.
Urol Oncol
. 2022 Nov;
41(2):104.e19-104.e27.
PMID: 36372633
Purpose: Magnetic resonance imaging (MRI) prior to biopsy has improved detection of clinically significant prostate cancer (CaP), but its impact on surgical outcomes is less well established. We compared MRI...